Takeda Files 6-K Report for June 2025
Ticker: TKPHF · Form: 6-K · Filed: Jun 10, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Takeda filed its monthly 6-K report on June 10, 2025, confirming its foreign private issuer status and 20-F filing for annual reports.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on June 10, 2025, reporting as a foreign private issuer. The filing is for the month of June 2025 and indicates Takeda will file its annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Takeda's status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 0001395064-25-000078 (accession_number) — Filing identifier
- June 10, 2025 (date) — Filing date
- Tokyo, Japan (location) — Principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information to the SEC that is made public in their home country or filed with a stock exchange.
Which form does Takeda use for its annual reports?
Takeda indicates it files its annual reports under cover of Form 20-F.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
What is the filing date of this specific 6-K report?
This specific 6-K report was filed on June 10, 2025.
Is Takeda submitting this Form 6-K in paper format?
The filing indicates that Takeda is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 10, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).